Wln: T D3 B556 BN EM JV mvttt&J GO1 H1ovz KO1 L1

Base Information

• Chemical Name: Wln: T D3 B556 BN EM JV mvttt&J GO1 H1ovz KO1 L1
• CAS No.: 4055-39-4
• Molecular Formula: C16H19 N3 O6
• Molecular Weight: 351.359
• NSC Number: 75986
• Wikidata: Q105035289
• Mol file: 4055-39-4.mol

Synonyms:NSC75986;SCHEMBL183169;AKOS030242076;WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KO1 L1;Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate;Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester);Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-

Chemical Property of Wln: T D3 B556 BN EM JV mvttt&J GO1 H1ovz KO1 L1

Chemical Property:

• Appearance/Colour: red-violet crystals
• Melting Point: 159-1610
• Refractive Index: 1.6500 (estimate)
• Boiling Point: 587.4 ºC at 760 mmHg
• PKA: 13.27±0.50(Predicted)
• Flash Point: 309.1 ºC
• PSA: 130.10000
• Density: 1.5
• LogP: 0.00350
• Storage Temp.: -20°C Freezer
• XLogP3: 0.3
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 5
• Exact Mass: 349.12738533
• Heavy Atom Count: 25
• Complexity: 772

Purity/Quality:

99% ^*data from raw suppliers

MitomycinA ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)OC
• Isomeric SMILES: CC1=C(C(=O)C2=C(C1=O)N3C[C@@H]4[C@H]([C@]3([C@H]2COC(=O)N)OC)N4)OC
• Uses: The 6-methoxy analog of Mitomycin C. An antitumor antibiotic

Technology Process of Wln: T D3 B556 BN EM JV mvttt&J GO1 H1ovz KO1 L1

There total 13 articles about Wln: T D3 B556 BN EM JV mvttt&J GO1 H1ovz KO1 L1 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 85.0%

(8aS)-8a-bromoalbomitomycin A (132732-87-7,132830-44-5) → mitomycin A (4055-39-4) + albomitomycin A (110934-24-2)

Guidance literature:

With 2,2'-azobis(isobutyronitrile); tri-n-butyl-tin hydride; In toluene; at 60 ℃; for 0.166667h;

DOI:10.1021/jo00052a052

Reference yield: 84.0%

mitomycin C (50-07-7) → mitomycin A (4055-39-4)

Guidance literature:

With potassium hydroxide; In methanol;

DOI:10.1021/jo00295a051

Reference yield: 65.0%

methanol (67-56-1) + 1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)-6-(phenylselenyl)mitomycin A (122644-74-0,122675-60-9,134679-23-5) → mitomycin A (4055-39-4)

Guidance literature:

With potassium carbonate; dimedone; Ambient temperature;

DOI:10.1021/jo00067a063

upstream raw materials:

diazomethane

7-hydroxy-9a-methoxymitosane

methanol

1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)-6-(phenylselenyl)mitomycin A

Downstream raw materials:

C₂₃H₂₆N₄O₇

C₂₃H₂₄N₄O₅

C₂₃H₂₆N₄O₆

C₂₂H₂₅N₅O₇S

Refernces

Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7

10.1021/jm00355a004

The research focuses on the development and evaluation of analogues of mitomycin C and porfiromycin with substituted ethylamines at position 7. These analogues were synthesized and tested for their antitumor activities against various mouse tumors, including P-388 leukemia, L-1210 leukemia, and B-16 melanoma. The study aimed to identify compounds that are at least as potent as mitomycin C but with reduced leukopenic effects. Key chemicals involved in the research include mitomycin C, porfiromycin, and a variety of ethylamine derivatives such as 2-phenylethylamine, 2-chloroethylamine, 2-hydroxyethylamine, and others with different functional groups at the 2-position of the ethylamine. The analogues were prepared using mitomycin A or N-methyl-mitomycin A as starting materials and various amines for substitution. The synthesized compounds were then purified, characterized, and tested for their biological activities. The results showed that some analogues exhibited better antitumor activity and reduced leukopenia compared to mitomycin C, with notable examples being the mercaptoethylamine analogue (8) and the fluoroethylamine analogue (4). The study also explored structure-activity relationships, finding a limited correlation between the potency of the analogues and their hydrophilicity.